NASDAQ$CRIS
Curis Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Curis reported financial results for the first quarter ended March 31, 2020.
Curis reported a net loss of $9.7 million, or $0.28 per share, for the first quarter of 2020. Revenues for the quarter were $2.7 million, primarily from royalty revenues on Genentech and Roche's Erivedge sales. The company's cash, cash equivalents, and investments totaled $12.5 million as of March 31, 2020.
- Advanced ongoing study for CA-4948.
- Accomplished key licensing and financial objectives.
- Implemented clinical and operational measures in response to the COVID-19 pandemic.
- Expects to initiate a Phase 1 trial of CA-4948 in patients with AML and MDS in the second quarter of 2020.
Headline financials
Revenue & EPS history
Curis · Revenue · Quarterly
$2.71M
Revenue by segment
Curis · $2.52M total across 1 segment · Q1 2020
- Royalties$2.52M+17.7%100.0%
Forward guidance
Curis expects that its existing cash, cash equivalents and investments should enable it to maintain its planned operations into the second half of 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2020
-1.7%
Avg return
Earnings day
-1.2%
Avg return
5 days after
+14.9%
Avg return
30 days after
37%
23 / 63 earnings
Positive
+46.2%
Q4 2017
Best reaction
-26.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.3% | -4.6% | — | |
| Q1 2026 | -9.5% | -13.1% | -23.7% | |
| Q3 2025 | -7.2% | -15.8% | -7.5% | |
| Q4 2024 | -9.5% | -38.6% | -32.4% | |
| Q3 2024 | +0.5% | -3.6% | -9.2% | |
| Q2 2024 | -8.8% | -12.4% | +0.9% | |
| Q1 2024 | +1.1% | -2.8% | -40.2% | |
| Q4 2023 | +10.9% | +8.0% | +11.8% | |
| Q3 2023 | -3.0% | +15.3% | +151.8% | |
| Q2 2023 | -11.5% | -17.7% | -26.6% | |
| Q1 2023 | -0.6% | +2.5% | +6.2% | |
| Q4 2022 | -10.9% | -14.3% | +31.7% | |
| Q3 2022 | +5.1% | +15.4% | -1.3% | |
| Q2 2022 | +2.0% | +0.0% | -7.1% | |
| Q1 2022 | -12.6% | +2.0% | -6.0% | |
| Q4 2021 | +9.2% | +15.7% | -15.4% | |
| Q3 2021 | -0.7% | -2.5% | -21.1% | |
| Q2 2021 | -6.9% | -10.1% | +13.9% | |
| Q1 2021 | +33.0% | +53.1% | -18.5% | |
| Q4 2020 | -1.7% | +10.2% | +10.8% | |
| Q3 2020 | +12.0% | +13.9% | +647.2% | |
| Q2 2020 | +16.8% | +19.3% | -16.0% | |
| Q1 2020 | -12.0% | -10.5% | +55.8% | |
| Q4 2019 | -7.1% | -4.2% | +9.7% | |
| Q3 2019 | -26.3% | -39.1% | -24.3% | |
| Q2 2019 | -21.3% | -20.9% | -18.3% | |
| Q1 2019 | -1.6% | -11.4% | -22.7% | |
| Q4 2018 | +5.8% | +5.3% | -5.8% | |
| Q3 2018 | +5.5% | -1.8% | -47.2% | |
| Q2 2018 | -9.8% | -12.4% | -12.4% | |
| Q1 2018 | -10.8% | -12.5% | -11.1% | |
| Q4 2017 | +46.2% | +43.9% | -5.3% | |
| Q3 2017 | -11.3% | -18.5% | -44.4% | |
| Q2 2017 | +0.0% | -1.2% | +21.5% | |
| Q1 2017 | -11.7% | -7.9% | -10.7% | |
| Q4 2016 | +16.1% | +12.5% | +2.0% | |
| Q3 2016 | -3.6% | +11.1% | +20.2% | |
| Q2 2016 | -1.7% | +1.1% | -3.4% | |
| Q1 2016 | +7.3% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | -9.7% | — | — | |
| Q1 2015 | +4.6% | — | — | |
| Q4 2014 | +0.3% | — | — | |
| Q3 2014 | -0.8% | — | — | |
| Q2 2014 | -7.8% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +11.4% | — | — | |
| Q3 2013 | -25.2% | — | — | |
| Q2 2013 | +3.0% | — | — | |
| Q1 2013 | -9.4% | — | — | |
| Q4 2012 | -4.0% | — | — | |
| Q3 2012 | -3.4% | — | — | |
| Q2 2012 | -0.9% | — | — | |
| Q1 2011 | +2.9% | — | — | |
| Q1 2012 | +0.6% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q3 2011 | -6.8% | — | — | |
| Q3 2010 | -6.8% | — | — | |
| Q2 2011 | -10.6% | — | — | |
| Q2 2010 | -10.6% | — | — | |
| Q4 2010 | +2.4% | — | — | |
| Q1 2010 | -6.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro